Quality of life data and COSENTYX®

COSENTYX® (secukinumab) is indicated for the treatment of:[1]

- Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
- Severe plaque psoriasis in pediatric patients 12 to less than 18 years of age who are candidates for systemic therapy or phototherapy and have a body weight ≥50 kg
- Adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX® can be used alone or in combination with methotrexate
- Adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy

Pr Cosentyx®
secukinumab

84%

improvement shown in DLQI[2] at week 52

COSENTYX® improved quality of life as measured by the DLQI* in patients with moderate to severe plaque psoriasis (secondary endpoint)

(mean % improvement from baseline) by patients on COSENTYX® 300 mg (n=331) vs. 75% by patients on ustekinumab (n=333); *p*=0.0002[2]*

Adapted from Blauvelt *et al.* 2017.

The total DLQI score includes the following subscale measures of patient QOL:

- Symptoms and feelings
- Daily activities
- Leisure
- Work and school
- Personal relationships
- Treatment

DLQI: dermatology quality of life index

* CLEAR was a phase 3b randomized, double-blind, active-comparator, parallel-group trial. Patients were randomized in a 1:1 ratio to receive subcutaneous injections of COSENTYX® 300 mg (n=337), or ustekinumab 45 mg or 90 mg for patients ≤100 kg and >100 kg, respectively (n=339). COSENTYX® injections were administered once weekly at Weeks 0, 1, 2 and 3, then monthly from Week 4 to Week 48. Ustekinumab injections were administered at Weeks 0, 4, 16, 28 and 40. Placebo injections matching the COSENTYX® dose regimen were given to subjects in the ustekinumab group to maintain blinding. Randomization was stratified by body weight (≤100 kg and >100 kg).[2]

Important safety information

Indication and clinical use:

COSENTYX® (secukinumab) is indicated for the treatment of:

- Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
- Severe plaque psoriasis in pediatric patients 12 to less than 18 years of age who are candidates for systemic therapy or phototherapy and have a body weight ≥50 kg
- Adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX® can be used alone or in combination with methotrexate
- Adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy

Geriatric patients ≥65 years of age: although limited in patient number, no differences in safety or efficacy were observed between older and younger patients.

Pediatrics <18 years of age: safety and effectiveness in pediatric patients with severe plaque psoriasis below the age of 12 years have not been established. Safety and effectiveness in pediatric patients with the principal diagnosis of psoriatic arthritis or ankylosing spondylitis below the age of 18 years have not been established.

Contraindications:

- Severe hypersensitivity to the active substance or any of its components

Relevant warnings and precautions:

- Infections: could potentially increase risk of infections; caution in patients with a chronic infection or history of recurrent infections; patients should be evaluated for tuberculosis prior to initiation of treatment with COSENTYX®
- Caution in patients with active inflammatory bowel disease
- Caution in latex-sensitive patients: natural rubber latex derivatives in the removable cap of the prefilled syringe/COSENTYX® SensoReady® pen
- Consider completion of all age-appropriate immunizations according to current guidelines prior to treatment; should not be used with live vaccinations; can be used with those that are inactivated or non-live
- Hypersensitivity reactions: rare cases of anaphylaxis and cases of urticaria occurred in COSENTYX®-treated patients in clinical trials
- Pregnancy: should only be used if the potential benefit justifies the potential risk to the fetus
- Nursing women: caution should be exercised

For more information:

Consult the Product Monograph at www.novartis.ca/CosentyxMonograph for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883.

References: 1. Cosentyx® Product Monograph, January 20, 2021. **2.** Blauvelt A, Reich K, Tsai T-F, *et al.* Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. *J Am Acad Dermatol.* 2017;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.0086.

NOVARTIS

Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
514.631.6775 514.631.1867

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

PrCosentyx® secukinumab